Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

…, M Sebastian, M Cernovska, H Coupkova… - The Lancet …, 2018 - thelancet.com
Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …

Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: data from the C zech TULUNG R egistry

…, J Krejci, O Fischer, M Zemanova, H Coupkova… - Thoracic …, 2020 - Wiley Online Library
Background Data regarding real‐life effectiveness of any treatment may improve clinical
decision‐making. The aim of this study was to evaluate real‐life effectiveness of tyrosin‐kinase …

Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation-a Case Report.

H Čoupková, R Vyzula - Klinicka Onkologie: Casopis Ceske a …, 2018 - europepmc.org
Conclusion With this patient, a partial response which lasted 19 months despite 50%
reduction of the afatinib dose was achieved. Key words: afatinib-non-small cell lung cancer-…

Real-life effectiveness of afatinib versus gefitinib in patients with non-small-cell lung cancer: a Czech multicentre study

…, M Hrnciarik, M Zemanova, H Coupkova… - Anticancer …, 2021 - ar.iiarjournals.org
Background/Aim: We investigated efficacy differences for afatinib versus gefitinib in non-small-cell
lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) mutations…

Prognostic value of EGFR Exon-20 insertions in Czech patients with advanced non-small cell lung cancer

…, J Blazek, M Svaton, J Krejci, H Coupkova… - Anticancer …, 2021 - ar.iiarjournals.org
Background/Aim: Per literature, patients with epidermal growth factor receptor (EGFR) exon-20
insertions respond poorly to tyrosine kinase inhibitors (TKIs). This study analyzed real-…

Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment

…, M Cernovska, M Hrnciarik, H Coupkova… - Anticancer …, 2021 - ar.iiarjournals.org
Background/Aim: Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab
are regimens used in combination with checkpoint inhibitors in non-squamous non-small …

Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment–prospective data from the Czech TULUNG registry

J Skřičková, P Májková, M Bařinová, M Bratová… - 2020 - Eur Respiratory Soc
Study evaluated the frequency of individual mutations before the start of the 1st and 2nd
generation TKI treatment, and determined in what material the mutations were identified and …

P2. 14-34 Tyrosine-Kinase Inhibitors (TKI) in First-Line Treatment of 470 Patients with Non-Small Cell Lung Cancer (NSCLC) from the Czech Republic

J Skřičková, P Májková, M Bařinová, M Pešek… - Journal of Thoracic …, 2019 - jto.org
Background From October 2013 there is a possibility to treat patients with NSCLC and with
activated epidermal growth factor receptor (EGFR) mutations with three TKI in the Czech …

The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients (pts)

J Skřičková, Z Bortlíček, K Hejduk, M Pešek… - Lung …, 2012 - lungcancerjournal.info
Background: The Czech Republic has had an opportunity to use pemetrexed for 1st line
treatment of advanced NSCLC from the year 2008. The purpose of this trial was to evaluate the …

P3. 02b-082 Gefitinib in First-Line Treatment of Caucasian Patients with NSCLC and EGFR Mutations in Exons 19 or 21: Topic: EGFR Clinical

…, M Zemanová, J Roubec, D Sixtova, H Coupkova… - Journal of Thoracic …, 2017 - jto.org
Background This study evaluates treatment outcomes in 182 NSCLC of Caucasian patients
from Czech Republic according to activated mutations located in exons 19 (Del19) and 21 (…